Diabetic Nephropathy: Emerging Biomarkers for Risk Assessment

Affiliations

¹ Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Pharmacology, Baylor College of Medicine, Houston, TX fdanesh@mdanderson.org.

Comment

Shawn S Badal et al. Diabetes. 2015 Sep.

. 2015 Sep;64(9):3063-5.

doi: 10.2337/db15-0738.

¹ Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Pharmacology, Baylor College of Medicine, Houston, TX fdanesh@mdanderson.org.

No abstract available

Figures

Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.
Pezzolesi MG, Satake E, McDonnell KP, Major M, Smiles AM, Krolewski AS. Pezzolesi MG, et al. Diabetes. 2015 Sep;64(9):3285-93. doi: 10.2337/db15-0116. Epub 2015 Apr 30. Diabetes. 2015. PMID: 25931475 Free PMC article.

1. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126–139 - PubMed
1. Liu C, Kelnar K, Liu B, et al. . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211–215 - PMC - PubMed
1. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775–789 - PMC - PubMed
1. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122—a key factor and therapeutic target in liver disease. J Hepatol 2015;62:448–457 - PubMed
1. Kato M, Castro NE, Natarajan R. MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med 2013;64:85–94 - PMC - PubMed